Attaching a light-sensitive cancer drug to an antibody fragment has boosted its potency while reducing its side effects.Photodynamic therapy relies on light-sensitive drugs that soak into tumours and then destroy them when flashed with light. The problem is that existing drugs soak into healthy tissue as well, where they take weeks to clear. As a result, patients risk scorching normal tissue during treatment and if they go into the sun afterwards.
